25/08/2021 (Agence Europe) – On Tuesday 24 August, the European Medicines Agency (EMA) gave its approval to increase the production capacity of the Covid-19 vaccine developed by Pfizer/BioNTech (Comirnaty): the agency approved a new manufacturing line at the German production site in Marburg as well as a new manufacturing site for the finished product, which will be located in France, in Saint-Rémy-sur-Avre. These changes are expected to increase the manufacturing capacity of the active substance by about 410 million doses in 2021 and to provide up to 51 million additional doses, according to the EMA. A new US manufacturing site as well as several sites responsible for batch control/testing and packaging of the vaccine developed by Moderna (Spikevax) have also been approved by the EMA. The company expects to produce an additional 40 million doses of Spikevax for the European market in the third quarter. (AC)